{"title":"扩大尼洛替尼在临床试验中的应用(ENACT):一项开放标签、多中心的口服尼洛替尼治疗伊马替尼耐药或伊马替尼不耐受费城染色体阳性慢性髓系白血病慢性期成年患者的研究","authors":"D. Signorelli","doi":"10.1016/J.YPAT.2012.11.022","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23782,"journal":{"name":"Yearbook of Pathology and Laboratory Medicine","volume":"1 1","pages":"367-368"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"23","resultStr":"{\"title\":\"Expanding Nilotinib Access in Clinical Trials (ENACT): An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase\",\"authors\":\"D. Signorelli\",\"doi\":\"10.1016/J.YPAT.2012.11.022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":23782,\"journal\":{\"name\":\"Yearbook of Pathology and Laboratory Medicine\",\"volume\":\"1 1\",\"pages\":\"367-368\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Yearbook of Pathology and Laboratory Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/J.YPAT.2012.11.022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yearbook of Pathology and Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/J.YPAT.2012.11.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Expanding Nilotinib Access in Clinical Trials (ENACT): An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase